Limits...
Experimental study of the mechanism of tolerance induction in dexamethasone-treated dendritic cells.

Gong YB, Huang YF, Li Y, Han GC, Li YR, Wang DJ, Du GP, Yu JF, Song J - Med. Sci. Monit. (2011)

Bottom Line: The expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells were analyzed with flow cytometry and the level of IL-12 secreted by DC2.4 cells was determined by ELISA.DC2.4 is a stable cell line with high expressions of CD80, CD86, and PD-L1.Dexamethasone does not significantly change the cell phenotype of DC2.4 cells, but inhibits the secretion of IL-12 cytokine and attenuates DC2.4's stimulation of the proliferation of allogeneic T cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China.

ABSTRACT

Background: The aim of this study was to investigate the mechanisms underlying tolerance induction of dexamethasone (Dex)-treated dendritic cells (DCs).

Material/methods: Well-grown DC2.4 cells were randomly assigned to receive control, 50 µg/L, 100 µg/L, or 200 µg/L of dexamethasone and then were cultured for 6 days. The expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells were analyzed with flow cytometry and the level of IL-12 secreted by DC2.4 cells was determined by ELISA. The stimulating activity of DC2.4 cells on allogeneic T cells was assessed with mixed lymphocyte reaction. Dexamethasone-treated DC2.4 cells were co-cultured with allogeneic splenic lymphocytes and the Foxp3 expression in naive T lymphocytes was determined with flow cytometry.

Results: Compared with the control group, the expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells exposed to different doses of dexamethasone showed no significant changes; however, dexamethasone treatment significantly reduced IL-12 secretion and inhibited DC2.4's stimulation on the proliferation of allogeneic T lymphocytes. Moreover, dexamethasone-treated DC2.4 cells effectively promoted FOXP3 expression in naive T lymphocytes.

Conclusions: DC2.4 is a stable cell line with high expressions of CD80, CD86, and PD-L1. Dexamethasone does not significantly change the cell phenotype of DC2.4 cells, but inhibits the secretion of IL-12 cytokine and attenuates DC2.4's stimulation of the proliferation of allogeneic T cells. Dexamethasone-treated DC2.4 cells also effectively promote FOXP3 expression in naive T lymphocytes.

Show MeSH

Related in: MedlinePlus

Cytometry showing the expression of CD4+FOXP3+. (A) the expression of CD4+FOXP3 in BALB/c T lymphocytes; (B) R1(the area of lymphocytes); (C) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with DC2.4; (D) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with Dex treated DC2.4 cells.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539585&req=5

f8-medscimonit-17-5-br125: Cytometry showing the expression of CD4+FOXP3+. (A) the expression of CD4+FOXP3 in BALB/c T lymphocytes; (B) R1(the area of lymphocytes); (C) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with DC2.4; (D) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with Dex treated DC2.4 cells.

Mentions: The CD4+FOXP3 expression was observed in 6.93±0.91% of control T cells, 15.17±1.04% of T cells stimulated by DC2.4, and 17.93±0.97% of T cells stimulated by dexamethasone-treated DC2.4 (F=103.391, P=0.000). Compared with the control group, DC2.4 effectively promoted the expression of CD4+FOXP3+ in naive T cells (P<0.05). Compared with the DC2.4 group, dexamethasone-treated DC2.4 effectively promoted the expression of CD4+FOXP3+ in naive T cells (P<0.05) (Figure 8).


Experimental study of the mechanism of tolerance induction in dexamethasone-treated dendritic cells.

Gong YB, Huang YF, Li Y, Han GC, Li YR, Wang DJ, Du GP, Yu JF, Song J - Med. Sci. Monit. (2011)

Cytometry showing the expression of CD4+FOXP3+. (A) the expression of CD4+FOXP3 in BALB/c T lymphocytes; (B) R1(the area of lymphocytes); (C) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with DC2.4; (D) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with Dex treated DC2.4 cells.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539585&req=5

f8-medscimonit-17-5-br125: Cytometry showing the expression of CD4+FOXP3+. (A) the expression of CD4+FOXP3 in BALB/c T lymphocytes; (B) R1(the area of lymphocytes); (C) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with DC2.4; (D) the expression of CD4+FOXP3 in BALB/c T lymphocytes co-cultured with Dex treated DC2.4 cells.
Mentions: The CD4+FOXP3 expression was observed in 6.93±0.91% of control T cells, 15.17±1.04% of T cells stimulated by DC2.4, and 17.93±0.97% of T cells stimulated by dexamethasone-treated DC2.4 (F=103.391, P=0.000). Compared with the control group, DC2.4 effectively promoted the expression of CD4+FOXP3+ in naive T cells (P<0.05). Compared with the DC2.4 group, dexamethasone-treated DC2.4 effectively promoted the expression of CD4+FOXP3+ in naive T cells (P<0.05) (Figure 8).

Bottom Line: The expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells were analyzed with flow cytometry and the level of IL-12 secreted by DC2.4 cells was determined by ELISA.DC2.4 is a stable cell line with high expressions of CD80, CD86, and PD-L1.Dexamethasone does not significantly change the cell phenotype of DC2.4 cells, but inhibits the secretion of IL-12 cytokine and attenuates DC2.4's stimulation of the proliferation of allogeneic T cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China.

ABSTRACT

Background: The aim of this study was to investigate the mechanisms underlying tolerance induction of dexamethasone (Dex)-treated dendritic cells (DCs).

Material/methods: Well-grown DC2.4 cells were randomly assigned to receive control, 50 µg/L, 100 µg/L, or 200 µg/L of dexamethasone and then were cultured for 6 days. The expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells were analyzed with flow cytometry and the level of IL-12 secreted by DC2.4 cells was determined by ELISA. The stimulating activity of DC2.4 cells on allogeneic T cells was assessed with mixed lymphocyte reaction. Dexamethasone-treated DC2.4 cells were co-cultured with allogeneic splenic lymphocytes and the Foxp3 expression in naive T lymphocytes was determined with flow cytometry.

Results: Compared with the control group, the expressions of CD80, CD86, galectin-9, and PD-L1 on the surface of DC2.4 cells exposed to different doses of dexamethasone showed no significant changes; however, dexamethasone treatment significantly reduced IL-12 secretion and inhibited DC2.4's stimulation on the proliferation of allogeneic T lymphocytes. Moreover, dexamethasone-treated DC2.4 cells effectively promoted FOXP3 expression in naive T lymphocytes.

Conclusions: DC2.4 is a stable cell line with high expressions of CD80, CD86, and PD-L1. Dexamethasone does not significantly change the cell phenotype of DC2.4 cells, but inhibits the secretion of IL-12 cytokine and attenuates DC2.4's stimulation of the proliferation of allogeneic T cells. Dexamethasone-treated DC2.4 cells also effectively promote FOXP3 expression in naive T lymphocytes.

Show MeSH
Related in: MedlinePlus